Business context and reporting period
This is Ekso Bionics Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2014—not a filing for Chronoscale Holdings Corp. or a quarterly report. The company designs and sells wearable exoskeletons for medical rehabilitation and develops technologies for industrial and military applications. In January 2014, it completed a merger with Ekso Bionics, Inc. and discontinued its former medical-supplies distribution business.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $5.327 million | $3.302 million |
| Gross profit / margin | $1.559 million / 29% | $0.587 million / 18% |
| Operating expenses | $18.353 million | $10.881 million |
| Operating loss | $16.794 million | $10.294 million |
| Net loss | $33.769 million | $11.887 million |
| Net loss per share | $0.43 | $0.57 |
| Cash used in operating activities | $15.007 million | $9.063 million |
Medical-device revenue rose 81% to $2.924 million; engineering-services revenue rose 42% to $2.403 million. Gross margin improved, while sales and marketing, research and development, and general and administrative costs increased substantially. The $16.485 million warrant-liability loss was non-cash and materially increased the reported net loss. The company recognized device revenue over the related maintenance period, usually three years, rather than entirely at shipment.
At year-end, cash was $25.190 million, total assets were $33.474 million, and stockholders’ equity was $22.800 million. Current assets were $29.300 million against current liabilities of $6.614 million. Convertible debt was zero; notes payable totaled approximately $118,000. Total liabilities were $10.674 million, including $7.307 million of deferred revenue. Operating cash outflow was funded principally through financing: net cash provided by financing activities was $40.879 million, including $21.961 million from the private placement and $21.412 million from warrant exercises. Capital expenditures and other investing uses totaled $1.487 million.
Material changes and notable developments
- Revenue increased 61% year over year, with growth in both medical devices and engineering services. The company reported shipping 64 medical units in 2014, including 55 unit sales; cumulative systems sold or rented exceeded 110.
- Operating expenses increased 69%, reflecting expanded staffing and commercial activity, higher research and development spending, and merger, public-company, and investor-relations costs.
- The November warrant amendment and exercise raised approximately $21.4 million net. Amending anti-dilution provisions also ended liability accounting for the warrants; 22.8 million warrant shares were exercised, and 13.8 million warrants remained outstanding at year-end.
- The merger and related financings materially changed the capital structure. Common shares outstanding increased to 101.6 million at year-end, with additional options and warrants outstanding.
- Lockheed Martin’s sale and lease of FORTIS units to the U.S. Navy generated the company’s first related royalty payments. The company also received a payment under an intellectual-property license to OttoBock.
Outlook, risks, and controls
No formal revenue or earnings guidance is provided. Management estimated that year-end cash and current operations could fund obligations into the second quarter of 2016, based on average monthly net cash use of about $1.25 million and assumptions including revenue and gross-profit growth. The company stated that significant additional financing would be required in the future; if financing is unavailable, it may need to reduce spending or curtail operations. Management’s longer-term goal was for one million people to stand and walk in Ekso exoskeletons by February 2022.
- FDA: In October 2014, the FDA issued an Untitled Letter stating that it believed Ekso GT fell within a new Class II powered-exoskeleton category requiring 510(k) clearance. The company submitted a 510(k) in December 2014, which remained under review at filing. It continued marketing under its existing registration, but acknowledged the FDA could require marketing to stop or products to be recalled.
- Commercial and development risks: The company had a limited commercialization history, long sales cycles, unproven broad market adoption, ongoing clinical-evidence needs, and products in development. It also faced competition, reimbursement uncertainty, manufacturing-cost challenges, and dependence on partners and grants.
- Funding and dilution: Continued losses and negative operating cash flow make future financing important. Equity financing could dilute stockholders; outstanding options and warrants add potential dilution.
- Financial reporting controls: Management concluded internal control over financial reporting and disclosure controls were not effective at December 31, 2014 because remediation measures had not operated long enough to be tested. The filing says the prior material weakness was considered remediated, but controls were not yet concluded effective. The auditor gave an unqualified opinion on the financial statements and did not attest to internal controls.
- Other: The filing reports no material legal proceedings and no off-balance-sheet arrangements. Foreign-currency-denominated sales were about 24% of revenue; management said a hypothetical 5% exchange-rate movement would have had an immaterial revenue effect.
Most important facts for investors to verify
- Confirm the issuer and reporting period: the supplied filing is Ekso Bionics Holdings, Inc.’s FY 2014 Form 10-K.
- Check the outcome and timing of the pending FDA 510(k), and whether marketing or labeling restrictions followed.
- Assess cash burn, financing needs, and whether the stated runway assumptions proved realistic.
- Review revenue recognition and deferred revenue, especially the multi-year recognition period for device sales.
- Track adoption, unit sales and rentals, gross margins, clinical-study results, and progress in reducing product costs.
- Evaluate potential dilution from outstanding options and warrants, alongside the thinly traded OTC market.
- Monitor remediation and testing of internal controls after management’s ineffective-controls conclusion.